Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8865796 | 0.85 | ADRA2A (0.49) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| SCHEMBL8865410 | 0.84 | ADRA2A (0.59) | ADRA2A | |
| SCHEMBL7103607 | 0.84 | ADRA2A (0.59) | ADRA2AOPRM1ADRA1AADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL8865395 | 0.83 | ADRA2A (0.57) | ADRA2A | |
| SCHEMBL8865236 | 0.82 | ADRA1A (0.51) | ADRA2AADRA1AADRA1DADRA1B | |
| SCHEMBL8866491 | 0.81 | P2RX7 (0.38) | ADRA2AHTR2COPRM1OPRD1OPRK1 | |
| SCHEMBL8986429 | 0.80 | ADRA2A (0.44) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| SCHEMBL769063 | 0.79 | ADRA1A (0.55) | ADRA2AOPRM1ADRA1AADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL8865343 | 0.78 | ADRA2A (0.43) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| SCHEMBL7035172 | 0.78 | ADRA1A (0.57) | ADRA2AADRA1AADRA1DADRA1BADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6479530-B2 | SUBSTITUTED 4(5)-(1-INDANYL,-INDANYLMETHYL, INDANYLMETHYLEN), 4(5)-(1-(1,2,3,4-TETRAHYDRONAPHTHYL, -NAPHTHYLMETHYL AND NAPHTHYLMETHYLEN)IMIDAZOLES; HYPOTENSIVE, ISCHEMIC AND ANXIOLYTIC AGENTS; NERVOUS AND MUSCULAR SYSTEM DISORDERS | ORION CORPORATION (FI) | 2002-11-12 | — | — | US | claimed |
| US-6479530-B2 | SUBSTITUTED 4(5)-(1-INDANYL,-INDANYLMETHYL, INDANYLMETHYLEN), 4(5)-(1-(1,2,3,4-TETRAHYDRONAPHTHYL, -NAPHTHYLMETHYL AND NAPHTHYLMETHYLEN)IMIDAZOLES; HYPOTENSIVE, ISCHEMIC AND ANXIOLYTIC AGENTS; NERVOUS AND MUSCULAR SYSTEM DISORDERS | ORION CORPORATION (FI) | 2002-11-12 | — | — | US | disclosed |
| US-20020007074-A1 | Imidazole derivatives having affinity for alpha2 receptors | KARJALAINEN ARTO (FI) | 2002-01-17 | — | — | US | disclosed |
| US-6313311-B1 | ADRENERGIC STIMULANTS FOR POTENTIATING ANESTHETICS PRIOR TO SURGERY; HYPOTENSIVE AGENTS, ANALGESICS, ANTIISCHEMIC AGENTS; NERVOUS SYSTEM AND PSYCHOLOGICAL DISORDERS | ORION CORPORATION (FI) | 2001-11-06 | — | — | US | disclosed |
| CN-1068592-C | Imidazole derivatives having affinity for alpha 2 receptors activity | ORION YHTYMAE OY (FI) | 2001-07-18 | — | — | CN | disclosed |
| EP-0888309-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | ORION CORPORATION (FI) | 1999-01-07 | — | — | EP | disclosed |
| CN-1198741-A | Imidazole derivatives having affinity for alpha 2 receptor activity | ORION YHTYMAE OY (FI) | 1998-11-11 | — | — | CN | disclosed |
| WO-1997012874-A1 | IMIDAZOLE DERIVATIVES HAVING AFFINITY FOR ALPHA2 RECEPTORS ACTIVITY | Orion-Yhtymä Oy (FI) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007074-A1 | Imidazole derivatives having affinity for alpha2 receptors | CHRM1, CHRNA1, CNR1 | ADRA2A 42/4885HTR2C 55/4885OPRM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.